NAD + Tirzepatide: Safety & Clinical Evidence

Last reviewed: May 28, 2026

Last updated: May 28, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

NAD (nicotinamide adenine dinucleotide) and tirzepatide target different metabolic pathways, and combining them may be discussed by patients seeking comprehensive metabolic support. However, no large clinical trials have specifically examined this combination, making provider guidance essential before starting either therapy.

Understanding your individual metabolic profile—including genetic predispositions in GLP-1 and metabolic regulation pathways—can help you and your provider make more informed decisions about whether combining these therapies aligns with your health goals and safety profile.

What NAD Does and How It Differs from Tirzepatide

NAD is a coenzyme essential for cellular energy production and mitochondrial function. It supports sirtuins, NAD-dependent enzymes involved in cellular repair and longevity pathways. Tirzepatide, by contrast, is a GLP-1 and GIP receptor agonist that regulates appetite, blood glucose, and metabolic rate through hormonal signaling.

While both may improve metabolic markers, they work through distinct biological mechanisms. NAD supplementation aims to restore cellular energy capacity, whereas tirzepatide acts on gut hormones. This difference means potential interactions are pharmacokinetic (drug metabolism) rather than direct pathway overlap, but medical evaluation is still necessary.

Mechanism Comparison: Cellular vs. Hormonal Metabolic Action

Understanding how these therapies differ helps clarify why combining them requires careful consideration. The table below outlines their primary mechanisms, target tissues, and metabolic endpoints.

Therapy	Primary Mechanism	Target Tissue	Metabolic Endpoint
NAD Supplementation	Restores mitochondrial coenzyme pools; activates sirtuins and PARPs	Mitochondria; neurons; muscle	Cellular energy; oxidative stress reduction
Tirzepatide	Dual GLP-1/GIP receptor agonism	Pancreatic beta cells; GI tract; CNS appetite centers	Insulin secretion; appetite suppression; glucose control
Interaction Risk	Indirect: shared metabolic load on liver metabolism	Hepatic CYP3A4 pathway	Potential altered bioavailability if NAD affects absorption
Clinical Evidence	NAD studies (aging, neuro, mitochondrial disease); tirzepatide RCTs (weight, glucose)	Separate patient populations	No dedicated co-administration trials published

Current Clinical Evidence on NAD and Tirzepatide Co-Use

No published randomized controlled trials directly assess NAD and tirzepatide together. Separate bodies of evidence support each therapy independently: tirzepatide shows robust weight loss and glycemic control in SURMOUNT and SURPASS trials; NAD studies focus on mitochondrial disease, neurodegenerative conditions, and aging biomarkers.

The absence of safety data does not mean combination is contraindicated, but it does mean shared decision-making with a healthcare provider is critical. Observational reports from practitioners combining these therapies are limited and not yet systematized in peer-reviewed literature.

Safety Considerations and Who Should Discuss This Combination

Tirzepatide carries known risks including nausea, pancreatitis risk assessment, and thyroid concerns (black-box warning for medullary thyroid carcinoma history). NAD supplementation is generally well-tolerated but may cause flushing and has minimal long-term safety data in high-dose protocols. Combining them increases the number of metabolic variables your provider must monitor.

This combination may be most relevant for individuals with metabolic dysfunction, fatigue linked to mitochondrial impairment, or weight loss resistance despite optimal GLP-1 dosing. However, only a qualified healthcare provider can assess whether your kidney function, liver metabolism, medication list, and medical history support this approach safely.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context about your individual predispositions in GLP-1R signaling (rs6923761), GIPR function (rs1800437), and metabolic regulation genes like MC4R and FTO. These genetic markers can support a more informed conversation with your provider about whether tirzepatide is a strong fit for your metabolic profile before considering additional therapies like NAD.

The genetic test reveals predispositions in peptide metabolic pathways, not exact medication response or NAD-tirzepatide interaction risk. However, understanding your baseline GLP-1 receptor genetics can help your provider personalize tirzepatide dosing and timing, which is important context if you are also considering NAD supplementation.

Combining this genetic insight with your current metabolic bloodwork (glucose, lipids, liver function, pancreatic enzymes) and your provider's clinical assessment creates a more complete picture for deciding whether NAD and tirzepatide are appropriate together for your health goals.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral is $349/mo month-to-month, or from $279/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What does NAD actually do that a GLP-1 medication does not?

NAD is a coenzyme central to cellular energy production and mitochondrial function, and it supports sirtuins, the enzymes involved in cellular repair and longevity pathways. Tirzepatide works at a completely different level, acting on gut hormone signalling to regulate appetite, blood glucose and metabolic rate. One aims at cellular energy capacity, the other at hormonal appetite control.

Is there any trial evidence for taking these two together?

None directly. No published randomized controlled trials assess NAD and tirzepatide in combination, so the evidence base is two separate literatures rather than one. Tirzepatide has the SURMOUNT and SURPASS trials behind it for weight and glucose outcomes, while NAD research has focused on mitochondrial disease, neurodegenerative conditions and aging biomarkers. Practitioner reports on combining them are limited and not systematized.

Does the lack of safety data mean the combination is off limits?

Not automatically. The article is careful on this point: absence of safety data does not mean the combination is contraindicated, but it does mean shared decision-making with a provider becomes critical rather than optional. Without published data to lean on, the decision rests on your own clinical picture. That is a conversation to have before starting either therapy, not after.

Which people are most likely to raise this combination with a provider?

The article points to individuals with metabolic dysfunction, people with fatigue linked to mitochondrial impairment, and those seeing weight loss resistance despite an optimised GLP-1 regimen. Being in one of those groups is a reason to ask the question, not an answer to it. Only a qualified provider can judge whether your kidney function, liver metabolism, medication list and history support the approach.

What extra safety monitoring does adding NAD create?

More variables to watch. Tirzepatide already carries known risks including nausea, a need for pancreatitis risk assessment and a boxed warning tied to medullary thyroid carcinoma history. NAD supplementation is generally well tolerated but may cause flushing and has minimal long-term safety data at high doses. Running both means your provider is monitoring two sets of effects rather than one.

Related Reading

• Can I Increase Nad Based On My Genetics
• Lifemd Tirzepatide
• Goodlife Meds Tirzepatide
• Noom Tirzepatide

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.